doi:10.48130/epi-0026-0009

[1]

Law JA, Jacobsen SE. 2010. Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nature Reviews Genetics 11(3):204−220

doi: 10.1038/nrg2719

[2]

Liu X, Nisa KU, Kong W, Lang Z, Niu Q. 2025. DNA methylation and histone modifications: conserved, divergent, and synergistic epigenetic regulation across plants and animals. Epigenetics Insights 18:e015

doi: 10.48130/epi-0025-0014

[3]

Meza-Menchaca T, Giancarlo VM, Melgar-Lalanne G, Ricaño-Rodríguez J, Aguirre-von-Wobeser E. 2025. Reframing epigenetics: three dimensions in the post-genomic era. Epigenetics Insights 18:e014

doi: 10.48130/epi-0025-0012

[4]

Wyatt GR. 1951. Recognition and estimation of 5-methylcytosine in nucleic acids. Biochemical Journal 48(5):581−584

doi: 10.1042/bj0480581

[5]

Dostal V, Churchill MEA. 2019. Cytosine methylation of mitochondrial DNA at CpG sequences impacts transcription factor A DNA binding and transcription. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1862(5):598−607

doi: 10.1016/j.bbagrm.2019.01.006

[6]

Widagdo J, Anggono V. 2018. The m6A-epitranscriptomic signature in neurobiology: from neurodevelopment to brain plasticity. Journal of Neurochemistry 147(2):137−152

doi: 10.1111/jnc.14481

[7]

Smith ZD, Hetzel S, Meissner A. 2025. DNA methylation in mammalian development and disease. Nature Reviews Genetics 26(1):7−30

doi: 10.1038/s41576-024-00760-8

[8]

Mulholland CB, Nishiyama A. 2025. Molecular mechanisms of maintenance DNA methylation. Genes & Genetic Systems 100:25

doi: 10.1266/ggs.25-00073

[9]

Bronner C, Alhosin M, Hamiche A, Mousli M. 2019. Coordinated dialogue between UHRF1 and DNMT1 to ensure faithful inheritance of methylated DNA patterns. Genes 10(1):65

doi: 10.3390/genes10010065

[10]

Anderson CM, Gillespie SL, Thiele DK, Ralph JL, Ohm JE. 2018. Effects of maternal vitamin D supplementation on the maternal and infant epigenome. Breastfeeding Medicine 13(5):371−380

doi: 10.1089/bfm.2017.0231

[11]

Masser DR, Hadad N, Porter H, Stout MB, Unnikrishnan A, et al. 2018. Analysis of DNA modifications in aging research. GeroScience 40(1):11−29

doi: 10.1007/s11357-018-0005-3

[12]

Jeltsch A, Broche J, Bashtrykov P. 2018. Molecular processes connecting DNA methylation patterns with DNA methyltransferases and histone modifications in mammalian genomes. Genes 9(11):566

doi: 10.3390/genes9110566

[13]

Zhang H, Liu H, Chen Y, Yang X, Wang P, et al. 2016. A cell cycle-dependent BRCA1–UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nature Communications 7:10201

doi: 10.1038/ncomms10201

[14]

Almalki NAR, Sabir JSM, Ibrahim A, Alhosin M, Asseri AH, et al. 2024. UHRF1 poly-auto-ubiquitination induced by the anti-cancer drug, thymoquinone, is involved in the DNA repair machinery recruitment. The International Journal of Biochemistry & Cell Biology 171:106582

doi: 10.1016/j.biocel.2024.106582

[15]

Feng L, Lou J. 2018. DNA methylation analysis. Nanotoxicity. New York, NY: Springer New York: 181−227 doi: 10.1007/978-1-4939-8916-4_12

[16]

Hermann A, Gowher H, Jeltsch A. 2004. Biochemistry and biology of mammalian DNA methyltransferases. Cellular and Molecular Life Sciences CMLS 61(19):2571−2587

doi: 10.1007/s00018-004-4201-1

[17]

Jeltsch A, Jurkowska RZ. 2016. Allosteric control of mammalian DNA methyltransferases–a new regulatory paradigm. Nucleic Acids Research 44(18):8556−8575

doi: 10.1093/nar/gkw723

[18]

Das R, Dimitrova N, Xuan Z, Rollins RA, Haghighi F, et al. 2006. Computational prediction of methylation status in human genomic sequences. Proceedings of the National Academy of Sciences of the United States of America 103(28):10713−10716

doi: 10.1073/pnas.0602949103

[19]

Rollins RA, Haghighi F, Edwards JR, Das R, Zhang MQ, et al. 2006. Large-scale structure of genomic methylation patterns. Genome Research 16(2):157−163

doi: 10.1101/gr.4362006

[20]

Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, et al. 2014. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26(4):577−590

doi: 10.1016/j.ccr.2014.07.028

[21]

Illingworth R, Kerr A, DeSousa D, Jørgensen H, Ellis P, et al. 2008. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biology 6(1):e22

doi: 10.1371/journal.pbio.0060022

[22]

Laurent L, Wong E, Li G, Huynh T, Tsirigos A, et al. 2010. Dynamic changes in the human methylome during differentiation. Genome Research 20(3):320−331

doi: 10.1101/gr.101907.109

[23]

Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, et al. 2009. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271):315−322

doi: 10.1038/nature08514

[24]

Nazarenko T, Vavourakis CD, Jones A, Evans I, Schreiberhuber L, et al. 2024. Technical and biological sources of unreliability of Infinium probes on Illumina methylation microarrays. Clinical Epigenetics 16(1):131

doi: 10.1186/s13148-024-01739-2

[25]

Šestáková Š, Šálek C, Remešová H. 2019. DNA methylation validation methods: a coherent review with practical comparison. Biological Procedures Online 21(1):19

doi: 10.1186/s12575-019-0107-z

[26]

Lövkvist C, Dodd IB, Sneppen K, Haerter JO. 2016. DNA methylation in human epigenomes depends on local topology of CpG sites. Nucleic Acids Research 44(11):5123−5132

doi: 10.1093/nar/gkw124

[27]

Pastor WA, Pape UJ, Huang Y, Henderson HR, Lister R, et al. 2011. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473(7347):394−397

doi: 10.1038/nature10102

[28]

Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, et al. 2005. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genetics 37(8):853−862

doi: 10.1038/ng1598

[29]

Portela A, Esteller M. 2010. Epigenetic modifications and human disease. Nature Biotechnology 28(10):1057−1068

doi: 10.1038/nbt.1685

[30]

Alhosin M, Sharif T, Mousli M, Etienne-Selloum N, Fuhrmann G, et al. 2011. Down-regulation of UHRF1 associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. Journal of Experimental & Clinical Cancer Research 30(1):41

doi: 10.1186/1756-9966-30-41

[31]

Alhosin M, Omran Z, Zamzami MA, Al-Malki AL, Choudhry H, et al. 2016. Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer. Journal of Experimental & Clinical Cancer Research 35:174

doi: 10.1186/s13046-016-0453-5

[32]

Xie S, Hagen D, Becker GM, Davenport KM, Shira KA, et al. 2025. Analyzing the relationship of RNA and DNA methylation with gene expression. Genome Biology 26(1):140

doi: 10.1186/s13059-025-03617-3

[33]

Neri F, Incarnato D, Krepelova A, Rapelli S, Anselmi F, et al. 2015. Single-base resolution analysis of 5-formyl and 5-carboxyl cytosine reveals promoter DNA methylation dynamics. Cell Reports 10(5):674−683

doi: 10.1016/j.celrep.2015.01.008

[34]

Yu M, Hon GC, Szulwach KE, Song CX, Jin P, et al. 2012. Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine. Nature Protocols 7(12):2159−2170

doi: 10.1038/nprot.2012.137

[35]

Bronner C, Achour M, ARIMA Y, Chataigneau T, Saya H, et al. 2007. The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future? Pharmacology & Therapeutics 115(3):419−434

doi: 10.1016/j.pharmthera.2007.06.003

[36]

Spruijt CG, Gnerlich F, Smits AH, Pfaffeneder T, Jansen PWTC, et al. 2013. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152(5):1146−1159

doi: 10.1016/j.cell.2013.02.004

[37]

Schoenfelder S, Fraser P. 2019. Long-range enhancer–promoter contacts in gene expression control. Nature Reviews Genetics 20(8):437−455

doi: 10.1038/s41576-019-0128-0

[38]

Choudalakis M, Kungulovski G, Mauser R, Bashtrykov P, Jeltsch A. 2023. Refined read-out: The hUHRF1Tandem-Tudor domain prefers binding to histone H3 tails containing K4me1 in the context of H3K9me2/3. Protein Science 32(9):e4760

doi: 10.1002/pro.4760

[39]

Choudalakis M, Bashtrykov P, Jeltsch A. 2024. RepEnTools: an automated repeat enrichment analysis package for ChIP-seq data reveals hUHRF1 Tandem-Tudor domain enrichment in young repeats. Mobile DNA 15(1):6

doi: 10.1186/s13100-024-00315-y

[40]

Swanberg SE, Nagarajan RP, Peddada S, Yasui DH, LaSalle JM. 2009. Reciprocal co-regulation of EGR2 and MECP2 is disrupted in Rett syndrome and autism. Human Molecular Genetics 18(3):525−534

doi: 10.1093/hmg/ddn380

[41]

Flam EL, Danilova L, Kelley DZ, Stavrovskaya E, Guo T, et al. 2019. Differentially methylated super-enhancers regulate target gene expression in human cancer. Scientific Reports 9:15034

doi: 10.1038/s41598-019-51018-x

[42]

Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, et al. 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153(2):307−319

doi: 10.1016/j.cell.2013.03.035

[43]

Pang P, Chen J, Li Q, Su Z, Lin J, et al. 2026. UHRF1-mediated DNA 5-mC modification drives super-enhancer redistribution and impedes osteogenesis via TGM2-regulated autophagic flux in senile osteoporosis. Journal of Advanced Research S 2090-1232(26):00346−2

doi: 10.1016/j.jare.2026.04.042

[44]

Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, et al. 2013. Global epigenomic reconfiguration during mammalian brain development. Science 341(6146):1237905

doi: 10.1126/science.1237905

[45]

Hahn O, Grönke S, Stubbs TM, Ficz G, Hendrich O, et al. 2017. Dietary restriction protects from age-associated DNA methylation and induces epigenetic reprogramming of lipid metabolism. Genome Biology 18(1):56

doi: 10.1186/s13059-017-1187-1

[46]

Pérez RF, Santamarina P, Tejedor JR, Urdinguio RG, Álvarez-Pitti J, et al. 2019. Longitudinal genome-wide DNA methylation analysis uncovers persistent early-life DNA methylation changes. Journal of Translational Medicine 17:15

doi: 10.1186/s12967-018-1751-9

[47]

Terekhova M, Swain A, Bohacova P, Aladyeva E, Arthur L, et al. 2023. Single-cell atlas of healthy human blood unveils age-related loss of NKG2C+GZMB−CD8⁺ memory T cells and accumulation of type 2 memory T cells. Immunity 56(12):2836−2854

doi: 10.1016/j.immuni.2023.10.013

[48]

Kim KY, Tanaka Y, Su J, Cakir B, Xiang Y, et al. 2018. Uhrf1 regulates active transcriptional marks at bivalent domains in pluripotent stem cells through Setd1a. Nature Communications 9:2583

doi: 10.1038/s41467-018-04818-0

[49]

Tiedemann RL, Hrit J, Du Q, Wiseman AK, Eden HE, et al. 2024. UHRF1 ubiquitin ligase activity supports the maintenance of low-density CpG methylation. Nucleic Acids Research 52(22):13733−13756

doi: 10.1093/nar/gkae1105

[50]

Papin C, Ibrahim A, Sabir JSM, Le Gras S, Stoll I, et al. 2023. MBD4 loss results in global reactivation of promoters and retroelements with low methylated CpG density. Journal of Experimental & Clinical Cancer Research 42(1):301

doi: 10.1186/s13046-023-02882-z

[51]

Catania S, Dumesic PA, Pimentel H, Nasif A, Stoddard CI, et al. 2020. Evolutionary persistence of DNA methylation for millions of years after ancient loss of a de novo methyltransferase. Cell 180(2):263−277

doi: 10.1016/j.cell.2019.12.012

[52]

Kikuchi A, Arita K. 2025. A comprehensive review of structural insights into DNA methylation maintenance. Genes & Genetic Systems 100:25−00051

doi: 10.1266/ggs.25-00051

[53]

Han M, Li J, Cao Y, Huang Y, Li W, et al. 2020. A role for LSH in facilitating DNA methylation by DNMT1 through enhancing UHRF1 chromatin association. Nucleic Acids Research 48(21):12116−12134

doi: 10.1093/nar/gkaa1003

[54]

Dong Q, Gong C, Jiang Q, Liu Y, Hu Y, et al. 2024. Identification of differentially expressed tumour-related genes regulated by UHRF1-driven DNA methylation. Scientific Reports 14:18371

doi: 10.1038/s41598-024-69110-2

[55]

Holliday R, Pugh JE. 1975. DNA modification mechanisms and gene activity during development. Science 187:226−232

doi: 10.1126/science.187.4173.226

[56]

Mattei AL, Bailly N, Meissner A. 2022. DNA methylation: a historical perspective. Trends in Genetics 38(7):676−707

doi: 10.1016/j.tig.2022.03.010

[57]

Bernstein C. 2022. DNA methylation and establishing memory. Epigenetics Insights 15:25168657211072499

doi: 10.1177/25168657211072499

[58]

Buck-Koehntop BA, Defossez PA. 2013. On how mammalian transcription factors recognize methylated DNA. Epigenetics 8(2):131−137

doi: 10.4161/epi.23632

[59]

Bronner C, Fuhrmann G, Chédin FL, Macaluso M, Dhe-Paganon S. 2009. UHRF1 links the histone code and DNA methylation to ensure faithful epigenetic memory inheritance. Genetics & Epigenetics 2:29−36

doi: 10.4137/geg.s3992

[60]

Maleknia M, Ahmadirad N, Golab F, Katebi Y, Haj Mohamad Ebrahim Ketabforoush A. 2023. DNA methylation in cancer: epigenetic view of dietary and lifestyle factors. Epigenetics Insights 16:25168657231199893

doi: 10.1177/25168657231199893

[61]

Jones PA, Issa JJ, Baylin S. 2016. Targeting the cancer epigenome for therapy. Nature Reviews Genetics 17(10):630−641

doi: 10.1038/nrg.2016.93

[62]

Bochtler M, Kolano A, Xu GL. 2017. DNA demethylation pathways: Additional players and regulators. BioEssays 39(1):1−13

doi: 10.1002/bies.201600178

[63]

Markiewicz E, Idowu OC. 2019. DNA damage in human skin and the capacities of natural compounds to modulate the bystander signalling. Open Biology 9(12):190208

doi: 10.1098/rsob.190208

[64]

Vito AF, Boesch DJ, Hammons AM, Freudenthal BD, Weaver TM. 2025. Base excision repair in chromatin: a tug-of-war for DNA damage. DNA Repair 155:103908

doi: 10.1016/j.dnarep.2025.103908

[65]

Zhou W, Jing X, Hang R, Liu Z, Cao L, et al. 2025. Base excision repair in human cancer: Emerging diagnostic and therapeutic target. DNA Repair 152:103879

doi: 10.1016/j.dnarep.2025.103879

[66]

Sjolund AB, Senejani AG, Sweasy JB. 2013. MBD4 and TDG: Multifaceted DNA glycosylases with ever expanding biological roles. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis 743−744:12−25

doi: 10.1016/j.mrfmmm.2012.11.001

[67]

Bellacosa A, Cicchillitti L, Schepis F, Riccio A, Yeung AT, et al. 1999. MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proceedings of the National Academy of Sciences of the United States of America 96(7):3969−3974

doi: 10.1073/pnas.96.7.3969

[68]

Koliadenko V, Wilanowski T. 2020. Additional functions of selected proteins involved in DNA repair. Free Radical Biology and Medicine 146:1−15

doi: 10.1016/j.freeradbiomed.2019.10.010

[69]

Hashimoto H, Zhang X, Cheng X. 2012. Excision of thymine and 5-hydroxymethyluracil by the MBD4 DNA glycosylase domain: structural basis and implications for active DNA demethylation. Nucleic Acids Research 40(17):8276−8284

doi: 10.1093/nar/gks628

[70]

Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, et al. 2003. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proceedings of the National Academy of Sciences of the United States of America 100(25):15071−15076

doi: 10.1073/pnas.2334585100

[71]

Branch P, Hampson R, Karran P. 1995. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Research 55:2304−2309

doi: 10.1158/0008-5472.CAN-55-11-2304

[72]

Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, et al. 2000. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Research 60(1):121−128

doi: 10.1158/0008-5472.CAN-99-2610

[73]

Achour M, Jacq X, Rondé P, Alhosin M, Charlot C, et al. 2008. The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 27(15):2187−2197

doi: 10.1038/sj.onc.1210855

[74]

Bostick M, Kim JK, Estève PO, Clark A, Pradhan S, et al. 2007. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317(5845):1760−1764

doi: 10.1126/science.1147939

[75]

Sharif J, Muto M, Takebayashi SI, Suetake I, Iwamatsu A, et al. 2007. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450(7171):908−912

doi: 10.1038/nature06397

[76]

Hashimoto H, Horton JR, Zhang X, Bostick M, Jacobsen SE, et al. 2008. The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. Nature 455(7214):826−829

doi: 10.1038/nature07280

[77]

Avvakumov GV, Walker JR, Xue S, Li Y, Duan S, et al. 2008. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature 455(7214):822−825

doi: 10.1038/nature07273

[78]

Arita K, Ariyoshi M, Tochio H, Nakamura Y, Shirakawa M. 2008. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature 455(7214):818−821

doi: 10.1038/nature07249

[79]

Yamaguchi K, Chen X, Rodgers B, Miura F, Bashtrykov P, et al. 2024. Non-canonical functions of UHRF1 maintain DNA methylation homeostasis in cancer cells. Nature Communications 15:2960

doi: 10.1038/s41467-024-47314-4

[80]

Nady N, Lemak A, Walker JR, Avvakumov GV, Kareta MS, et al. 2011. Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein. Journal of Biological Chemistry 286(27):24300−24311

doi: 10.1074/jbc.M111.234104

[81]

Bronner C, Chataigneau T, Schini-Kerth V, Landry Y. 2007. The "epigenetic code replication machinery", ECREM: a promising drugable target of the epigenetic cell memory. Current Medicinal Chemistry 14(25):2629−2641

doi: 10.2174/092986707782023244

[82]

Tauber M, Fischle W. 2015. Conserved linker regions and their regulation determine multiple chromatin-binding modes of UHRF1. Nucleus 6(2):123−132

doi: 10.1080/19491034.2015.1026022

[83]

Sidhu H, Capalash N. 2017. UHRF1: The key regulator of epigenetics and molecular target for cancer therapeutics. Tumor Biology 39(2):1010428317692205

doi: 10.1177/1010428317692205

[84]

Polepalli S, George SM, Valli Sri Vidya R, Rodrigues GS, Ramachandra L, et al. 2019. Role of UHRF1 in malignancy and its function as a therapeutic target for molecular docking towards the SRA domain. The International Journal of Biochemistry & Cell Biology 114:105558

doi: 10.1016/j.biocel.2019.06.006

[85]

Xue B, Zhao J, Feng P, Xing J, Wu H, et al. 2019. Epigenetic mechanism and target therapy of UHRF1 protein complex in malignancies. OncoTargets and Therapy 12:549−559

doi: 10.2147/OTT.S192234

[86]

Xie S, Qian C. 2018. The growing complexity of UHRF1-mediated maintenance DNA methylation. Genes 9(12):600

doi: 10.3390/genes9120600

[87]

Mancini M, Magnani E, Macchi F, Bonapace IM. 2021. The multi-functionality of UHRF1: epigenome maintenance and preservation of genome integrity. Nucleic Acids Research 49(11):6053−6068

doi: 10.1093/nar/gkab293

[88]

Kim A, Benavente CA. 2024. Oncogenic roles of UHRF1 in cancer. Epigenomes 8(3):26

doi: 10.3390/epigenomes8030026

[89]

Gu L, Fu Y, Li X. 2024. Roles of post-translational modifications of UHRF1 in cancer. Epigenetics & Chromatin 17(1):15

doi: 10.1186/s13072-024-00540-y

[90]

Dakal TC, Dhabhai B, Pant A, Moar K, Chaudhary K, et al. 2024. Oncogenes and tumor suppressor genes: functions and roles in cancers. MedComm 5(6):e582

doi: 10.1002/mco2.582

[91]

Valcárcel G, Lazarenkov A, López-Rubio AV, Berenguer C, Calafell-Segura J, et al. 2025. Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing. Science Advances 11(29):eadt1644

doi: 10.1126/sciadv.adt1644

[92]

Ashraf W, Ahmad T, Reynoird N, Hamiche A, Mély Y, et al. 2023. Natural and synthetic anticancer epidrugs targeting the epigenetic integrator UHRF1. Molecules 28(16):5997

doi: 10.3390/molecules28165997

[93]

Zhuo H, Tang J, Lin Z, Jiang R, Zhang X, et al. 2016. The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Molecular Carcinogenesis 55(2):209−219

doi: 10.1002/mc.22270

[94]

Ashraf W, Ibrahim A, Alhosin M, Zaayter L, Ouararhni K, et al. 2017. The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer. Oncotarget 8(31):51946−51962

doi: 10.18632/oncotarget.17393

[95]

Kostyrko K, Román M, Lee AG, Simpson DR, Dinh PT, et al. 2023. UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma. Nature Communications 14:3966

doi: 10.1038/s41467-023-39591-2

[96]

Pacaud R, Brocard E, Lalier L, Hervouet E, Vallette FM, et al. 2014. The DNMT1/PCNA/UHRF1 disruption induces tumorigenesis characterized by similar genetic and epigenetic signatures. Scientific Reports 4:4230

doi: 10.1038/srep04230

[97]

Jeanblanc M, Mousli M, Hopfner R, Bathami K, Martinet N, et al. 2005. The retinoblastoma gene and its product are targeted by ICBP90 a key mechanism in the G1/S transition during the cell cycle. Oncogene 24(49):7337−7345

doi: 10.1038/sj.onc.1208878

[98]

Ashraf W, Bronner C, Zaayter L, Ahmad T, Richert L, et al. 2017. Interaction of the epigenetic integrator UHRF1 with the MYST domain of TIP60 inside the cell. Journal of Experimental & Clinical Cancer Research 36(1):188

doi: 10.1186/s13046-017-0659-1

[99]

Achour M, Fuhrmann G, Alhosin M, Rondé P, Chataigneau T, et al. 2009. UHRF1 recruits the histone acetyltransferase Tip60 and controls its expression and activity. Biochemical and Biophysical Research Communications 390(3):523−528

doi: 10.1016/j.bbrc.2009.09.131

[100]

Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, et al. 2004. Down-regulation of nuclear protein ICBP90 by p53/p21^Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes to Cells 9(2):131−142

doi: 10.1111/j.1356-9597.2004.00710.x

[101]

Abusnina A, Alhosin M, Keravis T, Muller CD, Fuhrmann G, et al. 2011. Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis. Cellular Signalling 23(1):152−160

doi: 10.1016/j.cellsig.2010.08.015

[102]

Alhosin M, Abusnina A, Achour M, Sharif T, Muller C, et al. 2010. Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochemical Pharmacology 79(9):1251−1260

doi: 10.1016/j.bcp.2009.12.015

[103]

Hervouet E, Lalier L, Debien E, Cheray M, Geairon A, et al. 2010. Disruption of Dnmt1/PCNA/UHRF1 interactions promotes tumorigenesis from human and mice glial cells. PLoS One 5(6):e11333

doi: 10.1371/journal.pone.0011333

[104]

Chen J, Wang D, Wu G, Xiong F, Liu W, et al. 2024. STUB1-mediated K63-linked ubiquitination of UHRF1 promotes the progression of cholangiocarcinoma by maintaining DNA hypermethylation of PLA2G2A. Journal of Experimental & Clinical Cancer Research 43(1):260

doi: 10.1186/s13046-024-03186-6

[105]

Unoki M, Sasaki H. 2022. The UHRF protein family in epigenetics, development, and carcinogenesis. Proceedings of the Japan Academy, Series B 98(8):401−415

doi: 10.2183/pjab.98.021

[106]

Ren Y. 2022. Regulatory mechanism and biological function of UHRF1–DNMT1-mediated DNA methylation. Functional & Integrative Genomics 22(6):1113−1126

doi: 10.1007/s10142-022-00918-9

[107]

Kondo E, Gu Z, Horii A, Fukushige S. 2005. The thymine DNA glycosylase MBD4 represses transcription and is associated with Methylated p16INK4a and hMLH1 Genes. Molecular and Cellular Biology 25(11):4388−4396

doi: 10.1128/MCB.25.11.4388-4396.2005

[108]

Unoki M, Nishidate T, Nakamura Y. 2004. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23(46):7601−7610

doi: 10.1038/sj.onc.1208053

[109]

Thillainadesan G, Chitilian JM, Isovic M, Ablack JNG, Mymryk JS, et al. 2012. TGF-β-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex. Molecular Cell 46(5):636−649

doi: 10.1016/j.molcel.2012.03.027

[110]

Jia CY, Xiang W, Liu JB, Jiang GX, Sun F, et al. 2021. miR-9-1 suppresses cell proliferation and promotes apoptosis by targeting UHRF1 in lung cancer. Technology in Cancer Research & Treatment 20:15330338211041191

doi: 10.1177/15330338211041191

[111]

Meng H, Harrison DJ, Meehan RR. 2015. MBD4 interacts with and recruits USP7 to heterochromatic foci. Journal of Cellular Biochemistry 116(3):476−485

doi: 10.1002/jcb.25001

[112]

Silveira AB, Houy A, Ganier O, Özemek B, Vanhuele S, et al. 2024. Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes. Nature Communications 15:9864

doi: 10.1038/s41467-024-54223-z

[113]

Ibrahim A, Alhosin M, Papin C, Ouararhni K, Omran Z, et al. 2018. Thymoquinone challenges UHRF1 to commit auto-ubiquitination: a key event for apoptosis induction in cancer cells. Oncotarget 9(47):28599−28611

doi: 10.18632/oncotarget.25583

[114]

Ruzov A, Shorning B, Mortusewicz O, Dunican DS, Leonhardt H, et al. 2009. MBD4 and MLH1 are required for apoptotic induction in xDNMT1-depleted embryos. Development 136(13):2277−2286

doi: 10.1242/dev.032227

[115]

Yang Y, Liu G, Qin L, Ye L, Zhu F, et al. 2019. Overexpression of UHRF1 and its potential role in the development of invasive ductal breast cancer validated by integrative bioinformatics and immunohistochemistry analyses. Translational Cancer Research 8(4):1086−1096

doi: 10.21037/tcr.2019.06.19

[116]

Choudhry H, Zamzami M, Omran Z, Wu W, Mousli M, et al. 2017. Targeting microRNA/UHRF1 pathways as a novel strategy for cancer therapy (Review). Oncology Letters 15:3−10

doi: 10.3892/ol.2017.7290

[117]

The Human Protein Atlas. www.proteinatlas.org/ENSG00000129071-MBD4/cancer

[118]

Tien AL, Senbanerjee S, Kulkarni A, Mudbhary R, Goudreau B, et al. 2011. UHRF1 depletion causes a G2/M arrest, activation of DNA damage response and apoptosis. Biochemical Journal 435(1):175−185

doi: 10.1042/bj20100840

[119]

Zastko L. 2025. Genetic regulation of DNA double-strand breaks and repair pathways. Frontiers in Bioscience-Scholar 17(4):46225

doi: 10.31083/fbs46225

[120]

Mistry H, Tamblyn L, Butt H, Sisgoreo D, Gracias A, et al. 2010. UHRF1 is a genome caretaker that facilitates the DNA damage response to γ-irradiation. Genome Integrity 1:7

doi: 10.1186/2041-9414-1-7

[121]

DaRosa PA, Harrison JS, Zelter A, Davis TN, Brzovic P, et al. 2018. A bifunctional role for the UHRF1 UBL domain in the control of hemi-methylated DNA-dependent histone ubiquitylation. Molecular Cell 72(4):753−765

doi: 10.1016/j.molcel.2018.09.029

[122]

Ciaco S, Mazzoleni V, Javed A, Eiler S, Ruff M, et al. 2023. Inhibitors of UHRF1 base flipping activity showing cytotoxicity against cancer cells. Bioorganic Chemistry 137:106616

doi: 10.1016/j.bioorg.2023.106616

[123]

Kamel EM, Ali MAM, Allam AA, Ahmed NA, Abalkhail A, et al. 2025. Disrupting the epigenetic alliance: structural insights and therapeutic strategies targeting DNMT1–UHRF1. Functional & Integrative Genomics 25(1):194

doi: 10.1007/s10142-025-01708-9

[124]

Fu Y, Jiang L, Xie G, Peng Y, Fu Y, et al. 2025. A Hybrid compound H93 treats prostate cancer by directly binding UHRF1 and promoting protein dimerization. Communications Chemistry 8:356

doi: 10.1038/s42004-025-01744-3

[125]

Akrani I, Driva D, Tsakalidis E, Mozumdar N, Mavridi D, et al. 2025. Discovery and characterization of uracil derivatives targeting the set-and-ring domain of UHRF1. Journal of Chemical Information and Modeling 65(17):9274−9286

doi: 10.1021/acs.jcim.5c01345

[126]

Giovinazzo H, Walker D, Wyhs N, Liu J, Esopi DM, et al. 2019. A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs. Oncotarget 10(32):3040−3050

doi: 10.18632/oncotarget.26889

[127]

Bellacosa A, Drohat AC. 2015. Role of base excision repair in maintaining the genetic and epigenetic integrity of CpG sites. DNA Repair 32:33−42

doi: 10.1016/j.dnarep.2015.04.011

[128]

Screaton RA, Kiessling S, Sansom OJ, Millar CB, Maddison K, et al. 2003. Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: a potential link between genome surveillance and apoptosis. Proceedings of the National Academy of Sciences of the United States of America 100(9):5211−5216

doi: 10.1073/pnas.0431215100